Your AccountMS Treatments
15.02.2022This table contains a 2022 update of all existent MS treatment in the European Union, approved in a centralised procedure by the European Medicines Agency (EMA) or decentralised at national level.
To obtain more treatment-related information click on the names mentioned under ‘Commercial brand’.
The active links send to the EMA website. Once there, click on the EU flag in the top right corner of the screen to select your preferred language.
*Table entries are introduced in a random order
Disease-Modifying Therapies (DMTs)
Activesubstance |
Commercial brand |
Pharmaceuticalcompany |
Year ofapproval |
Type and frequency of administration |
|
Glatiramer acetate
|
Copaxone® 40MG/ML Copaxone® 20MG/ML
|
Teva Pharmaceuticals Ltd |
2004 and 2015 |
Subcutaneous. Daily or three times per week |
Glatiramer acetate |
Glatiramer Mylan 20 or 40 mg (Generic of Copaxone ® ) |
Mylan |
2016 and 2017 |
Subcutaneous. Daily or three times per week |
|
Alemtuzumab |
|
Genzyme Therapeutics Ltd |
2013 |
Intravenous. Three treatment cycles of five days each per year |
Cladribine |
Mavenclad® |
Merck |
2017 |
Oral. Two courses of treatment throughout 2 years |
|
Dimethyl fumarate |
|
Biogen |
2014 |
Oral. Twice per day |
|
Interferon beta-1a
|
|
Biogen |
1997 |
Intramuscular. Once per week |
|
Interferon beta-1a |
|
Merck |
1998 |
Subcutaneous. Three times per week |
|
Interferon beta-1b
|
Bayer Pharma Ag |
1995 |
Subcutaneous. Every two days |
|
|
Interferon beta-1b
|
Novartis Europharm Ltd |
2008 |
Subcutaneous. Every two days |
|
|
Peginterferon beta-1a
|
Biogen |
2014 |
Subcutaneous. Every two weeks |
|
|
Fingolimod
|
Novartis Europharm Ltd |
2011 |
Oral. Daily |
|
|
Mitoxantrone (generic since 2006) |
Meda Pharma S.A.U
|
1998 |
Intravenous. Variable frequency. Maximum cumulative dose: 140 mg/ m² |
|
|
Natalizumab |
Biogen |
2006 |
Intravenous. Every four weeks
|
|
| Ocrelizumab | Ocrevus® | Roche | 2018 | Intravenous. Every six months |
|
Ofatumumab |
|
Novartis Europharm Ltd |
2021 |
Subcutaneous. Every four weeks
|
|
Ozanlimod |
|
Bristol-Myers Squibb Pharma EEIG |
2020 |
Oral. Daily
|
|
Ponesimod |
Janssen-Cilag International N.V. |
2021 |
Oral. Daily
|
|
|
Siponimod |
Novartis Europharm Ltd |
2020 |
Oral. Daily
|
|
|
Teriflunomide |
Sanofi-Aventis | 2013 |
Oral. Daily
|
Symptomatic treatments
Activesubstance |
Commercial brand |
Pharmaceuticalcompany |
Year ofapproval |
Type and frequency of administration |
|
Cannabidiol / delta-9-tetrahydrocannabinol |
|
Almirall, S.A. |
2011 |
Oromucosal spray for oral use (4 weeks trial) – individualized number of sprays per day
|
Fampridine |
Fampyra® |
Biogen | 2011 | Oral. Twice per day |
Table reproduced with the courtesy of our member society Esclerosis Multiple Espana (EME).
